Centering discussion on a patient case of metastatic breast cancer, expert oncologist Hope Rugo, MD, FASCO, highlights systemic therapy selection and best practices in this setting.
EP. 2: The Role of ESR1 Mutations and Approaches to Biomarker Testing in Endocrine-Resistant Breast CancerMarch 22nd 2023
Expert perspective on the role of ESR1 mutations in HR+/HER2- mBC and best practices on biomarker testing for patients experiencing disease progression on endocrine therapy.
EP. 3: Treatment Options for HR+/HER2- Metastatic Breast Cancer with Disease Progression on Standard-of-Care TherapyMarch 22nd 2023
A comprehensive review of treatment options for patients with HR+/HER2- metastatic breast cancer who experience disease progression on standard-of-care therapies such as combination CDK4/6 and aromatase inhibitors.
EP. 5: Selecting Optimal Second- and Third-Line Therapy for HR+/HER2- mBCMarch 22nd 2023
Dr Hope Rugo shares insight on how she approaches second-line and higher treatment selection in patients with HR+/HER2- metastatic breast cancer who experience disease progression on first-line therapy.